Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by SundayMovieson Dec 09, 2022 8:15am

251 Views

Post# 35161186

Interim Results - Goblet & Adlai

Results for Goblet and Adlai are Interim Results. This obvious but needs to be said. The results can now only get better hereone.

Interim Goblet results got a FDA fast track designatina
Interim Adlai resutls will certainly get us more than just a partnership.

Adlai might be the friendly takeover partner going foward.

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment